ENDOMETRIAL CARCINOSARCOMA WITH ENDOMETRIOID EPITHELIAL COMPONENT
Clinical trials for ENDOMETRIAL CARCINOSARCOMA WITH ENDOMETRIOID EPITHELIAL COMPONENT explained in plain language.
Never miss a new study
Get alerted when new ENDOMETRIAL CARCINOSARCOMA WITH ENDOMETRIOID EPITHELIAL COMPONENT trials appear
Sign up with your email to follow new studies for ENDOMETRIAL CARCINOSARCOMA WITH ENDOMETRIOID EPITHELIAL COMPONENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail aims to outsmart resistant uterine cancer
Disease control Recruiting nowThis phase 2 trial tests whether combining hormone therapy (letrozole) with a targeted drug (abemaciclib), and possibly adding metformin or gedatolisib, can control estrogen-receptor-positive endometrial cancer that has returned or spread. The study enrolls adults with this cance…
Matched conditions: ENDOMETRIAL CARCINOSARCOMA WITH ENDOMETRIOID EPITHELIAL COMPONENT
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug combo aims to stall endometrial cancer in High-Risk patients
Disease control Recruiting nowThis study tests whether two drugs, abemaciclib and letrozole, can help keep advanced or recurrent endometrial cancer from getting worse. About 32 people with a specific type of estrogen-sensitive cancer will take these pills daily after initial treatment. The goal is to see if t…
Matched conditions: ENDOMETRIAL CARCINOSARCOMA WITH ENDOMETRIOID EPITHELIAL COMPONENT
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC